STVN

ATLANTA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Stevanato Group S.p.A. (“Stevanato” or the “Company”) (NYSE: STVN) complied with federal securities laws. On November 3, 2026, Stevanato reported third quarter 2026 financial results and on the accompanying earnings call revealed that “Revenue related to GLP-1s decreased in the third quarter and was approximately 17% to 18% of the total company revenue.” On this news, the price of the Company's stock dropped.

Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of Stevanato Group (STVN) investors following the Company's stock price decline

Stevanato Group NYSE: STVN reported third-quarter 2026 revenue growth of 8% to €326.1 million, supported by continued expansion in its biopharmaceutical and diagnostic solutions business despite weaker demand tied to GLP-1 therapies and a decline in its engineering segment.

STVN shares fell on November 3, 2026, as the market reacted to a lower GLP-1 revenue outlook in Stevanato Group's pre-market third-quarter results, the issue previews had flagged as the quarter's key test. SueWallSt notifies investors of a pending investigation into whether the Company's disclosures to investors met U.S. securities law requirements.

Stevanato Group (STVN) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.16 per share a year ago.

The Conestoga Small Cap Composite returned -11.22% net of fees in 3Q26, trailing the -9.39% return for the Russell 2000 Growth Index. Small Cap Composite top 5 leaders include Repligen, Merit Medical, Stevanato Group, Descartes Systems and Digi International. Small Cap Composite bottom 5 laggards include Mercury Systems, AAON, RBC Bearings, SPX Technologies and UL Solutions.

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN) (the “Company”), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced a collaboration with Aptar Pharma to provide system-level data supporting earlier evaluation of pre-filled syringe configurations for biotech and pharmaceutical companies, with a focus on sensitive biologics and other injectable therapie.

The Sustainable Value Strategy trailed its benchmark, the Russell 2500 Value Index, in the third quarter. New positions include Lineage, Birkenstock, Matador Resources, KBR and ICON. InterDigital, Stevanato Group and Exelixis rounded out our top contributors.

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third quarter of 2026 on Tuesday, November 3, 2026, at 6:30 a.m. (EDT). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (EDT) on Tuesday, November 3, 2026, to di.

Stevanato Group S.p.A. (STVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript